Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, Sep 1997, 515-518, Vol 4, No. 5
PC Woo, CY Lo, SK Lo, H Siau, JS Peiris, SS Wong, WK Luk, TM Chan, WW Lim and KY Yuen
A prospective study of the spectrum of glycoprotein B (gB) and glycoprotein
H (gH) genotypes of cytomegalovirus (CMV) was conducted with five
categories of patients: viremic bone marrow-transplant (BMT) recipients who
developed CMV disease after BMT (n = 22), viremic BMT recipients without
CMV disease (n = 11), viremic renal-transplant recipients who developed CMV
disease after transplantation (n = 14), viremic renal-transplant recipients
without CMV disease (n = 13), and premature babies with asymptomatic
congenital CMV infections (n = 13). Genotypic stability was observed
because the gB and gH genotypes of multiple isolates obtained from a single
patient were identical. The distribution of gH genotypes in patients of all
groups studied were similar. However, there was a unique distribution of
the gB genotype in the first category of patients, i.e., BMT recipients
with CMV disease, which was distinct from those of all other categories (P
< 0.05). CMV isolates from 54% of BMT recipients with CMV disease
exhibited gB type 2, while isolates from 46, 50, 69, and 77% of the BMT
recipients without CMV disease, renal-transplant recipients with and those
without CMV disease, and premature babies with congenital CMV infection,
respectively, were of gB type 1. An analysis of the clinical
characteristics of BMT recipients with CMV disease indicated that all
underwent either an allogeneic or matched, unrelated donor transplant, and
half had severe acute graft-versus-host disease (grades 2 to 4). The
statistically significant genotypic difference between CMV isolates from
BMT recipients with and without CMV disease was not observed between
isolates from renal-transplant recipients with and without CMV disease. We
speculate that differences in pathogenesis in different patient groups
might account for these observations. These findings would also facilitate
decision making about the choice of recombinant CMV glycoprotein vaccine
required to immunize transplant donors and the subsequent adoptive transfer
of immunity to BMT recipients. When the source of CMV DNA required for
genotyping was investigated among renal- transplant recipients, direct use
of peripheral blood leukocytes was 95% effective compared to the
effectiveness of cells obtained from conventional culture of peripheral
blood specimens.
Copyright © 1997 by the American Society for Microbiology. All rights reserved.
Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease
Department of Microbiology, The University of Hong Kong, Hong Kong.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |